The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women
Abstract
Objective To examine the effect of hormone replacement therapy on life expectancy in postmenopausal women with different risk profiles for heart disease, breast cancer, and hip fracture. Design Decision analysis using a Markov model. Published regression models were used to link risk factors to disease incidence and to estimate the lifetime risks of developing coronary heart disease (CHD), breast cancer, hip fracture, and endometrial cancer. The impact of hormone therapy on disease incidence was estimated from published epidemiologic studies. Setting Mathematical model applicable to primary care. Interventions Treatment with hormone replacement therapy or no hormone replacement therapy. Main outcome measure Life expectancy. Results Hormone replacement therapy should increase life expectancy for nearly all postmenopausal women, with some gains exceeding 3 years, depending mainly on an individual's risk factors for CHD and breast cancer. For women with at least 1 risk factor for CHD, hormone therapy should extend life expectancy, even for women having first-degree relatives with breast cancer. Women without any risk factors for CHD or hip fracture, but who have 2 first-degree relatives with breast cancer, however, should not receive hormone therapy. Conclusions The benefit of hormone replacement therapy in reducing the likelihood of developing CHD appears to outweigh the risk of breast cancer for nearly all women in whom this treatment might be considered. Our analysis supports…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STMs used to evaluate primary prevention strategies are concerned with reduction in the risk of developing a disease (e.g., [15]).”
From State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 (2012) · cites this paper as [15]
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Postmenopausal Estrogen Therapy and Cardiovascular Disease
Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., ROSNER, B. A., Speizer, F. E., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109123251102 · Cited by 2,000
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,611
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Cited by
Sorted by citations
Dietary Isoflavones: Biological Effects and Relevance to Human Health
Setchell, K. D. R., & Cassidy, A. (1999) · Journal of Nutrition · doi:10.1093/jn/129.3.758s · Cited by 1,163
Cardiovascular Disease in Women
Mosca, L. J., Manson, J. E., Sutherland, S. E., Langer, R. D., Manolio, T. A., & Barrett-Connor, E. L. (1997) · Circulation · doi:10.1161/01.cir.96.7.2468 · Cited by 733
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
Walsh, B. W. (1998) · JAMA · doi:10.1001/jama.279.18.1445 · Cited by 691
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases
Redelmeier, D. A., Tan, S. H., & Booth, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382106 · Cited by 634
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS
Barrett-Connor, E. L., & Grady, D. G. (1998) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.19.1.55 · Cited by 586
Metadata
- Authors
- Col, N. F.
- Affiliations
- Tufts University (US)
- Corresponding author
- Col, Nananda F.
- ORCID
- Col, Nananda F.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1997-04-09
- Volume
- 277
- Issue
- 14
- Pages
- 1140
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1983608420
- Cited by
- 229
- References
- 101
- Citations by year
- 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 27.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality (1 PO1 HS 06503)
- U.S. National Library of Medicine (LM07092, T15LM007092)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- hormone replacement therapy, postmenopausal women, life expectancy, coronary artery disease, breast cancer, hip fracture, endometrial cancer, cardiovascular risk factors, family history of breast cancer, individualized treatment decision-making
- MeSH terms
- Aged, Breast Neoplasms, Coronary Disease, Decision Support Techniques, Female, Hip Fractures, Humans, Life Expectancy, Middle Aged, Models, Theoretical, Risk, Risk Factors, Sensitivity and Specificity, Estrogen Replacement Therapy, Endometrial Neoplasms, Postmenopause, Black People, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
